





Original article

No evidence that genetic predictors of susceptibility predict changes in core outcomes in JIA

Annie Yarwood ^{1,2}, Stephanie Shoop-Worrall^{3,4}, Elena López-Isac⁵, Samantha Louise Smith ¹, Andrew P. Morris^{1,2}; Childhood Arthritis Prospective Study (CAPS) group*, John David Bowes ^{1,2}, Melissa Tordoff¹, Kimme L. Hyrich ^{2,3}, Wendy Thomson^{1,2} and Stephen Eyre¹

Abstract

Objectives. The clinical progression of JIA is unpredictable. Knowing who will develop severe disease could facilitate rapid intensification of therapies. We use genetic variants conferring susceptibility to JIA to predict disease outcome measures.

Methods. A total of 713 JIA patients with genotype data and core outcome variables (COVs) at diagnosis (baseline) and 1 year follow-up were identified from the Childhood Arthritis Prospective Study (CAPS). A weighted genetic risk score (GRS) was generated, including all single nucleotide polymorphisms (SNPs) previously associated with JIA susceptibility (P -value $< 5 \times 10^{-08}$). We used multivariable linear regression to test the GRS for association with COVs (limited joint count, active joint count, physician global assessment, parent/patient general evaluation, childhood HAQ and ESR) at baseline and change in COVs from baseline to 1 year, adjusting for baseline COV and International League of Associations of Rheumatology (ILAR) category. The GRS was split into quintiles to identify high (quintile 5) and low (quintile 1) risk groups.

Results. Patients in the high-risk group for the GRS had a younger age at presentation (median low risk 7.79, median high risk 3.51). No association was observed between the GRS and any outcome measures at 1 year follow-up or baseline.

Conclusion. For the first time we have used all known JIA genetic susceptibility loci ($P = < 5 \times 10^{-08}$) in a GRS to predict changes in disease outcome measured over time. Genetic susceptibility variants are poor predictors of changes in core outcome measures, it is likely that genetic factors predicting disease outcome are independent to those predicting susceptibility. The next step will be to conduct a genome-wide association analysis of JIA outcome.

Key words: JIA, genetics, disease outcome

Rheumatology key messages

- A genetic risk score of JIA susceptibility variants is not associated with disease outcome at 1 year.
- Genetic predictors of JIA outcome are likely to be independent of susceptibility variants.
- A GWAS of JIA outcome is required to identify true genetic predictors of outcome.

¹Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, ²NIHR Manchester Musculoskeletal Biomedical Research Centre, Manchester Academic Health Science Centre, Central Manchester University Hospitals NHS Foundation Trust, ³Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology Medicine and Health, Manchester Academic Health Science Centre, ⁴Centre for Health Informatics, The University of Manchester, Manchester, UK and ⁵Department of Biochemistry and Molecular Biology II, The University of Granada, Andalucía, Spain

Submitted 5 July 2021; accepted 15 December 2021

Correspondence to: Stephen Eyre, Centre for Genetics and Genomics Versus Arthritis, AV Hill Building, The University of Manchester, Manchester M13 9PT, UK. E-mail: Kimme.Hyrich@manchester.ac.uk

*See [supplementary data](#) available at *Rheumatology* online for a list of the Childhood Arthritis Prospective Study (CAPS) Group members.

Introduction

JIA is the most common inflammatory rheumatic condition in children and young people (CYP) under 16 years of age, affecting ~12 000 CYP in the UK. JIA is an umbrella term that encompasses a group of conditions characterized by inflammatory arthritis and are classified by the ILAR classification system [1]. ILAR classification uses clinical and laboratory features to identify clinically homogeneous groups of patients. However, the clinical progression of JIA is unpredictable with patients often experiencing differing symptoms and varying prognosis [2]. Some patients may experience mild and short periods of inflammation in a single joint, whereas others can experience long-lasting inflammation in multiple joints, which can lead to joint damage/destruction and long-term disability. However, remission is achievable with the use of medication, and outcome of disease has significantly improved since the introduction of biologic therapies. Despite within-group heterogeneity, the best current predictor of outcome in JIA is ILAR category, where patients with oligoarthritis have been shown to have increased rates of inactive disease/remission, while patients with RF-positive polyarthritis have the poorest outcomes [3, 4]. Age at onset and sex have also been associated with achieving clinically inactive disease/remission, with younger age at onset being associated with more severe disease and a decreased chance of inactive disease [5, 6], and female sex associated with higher levels of physical disability [6], although these associations are not often evident after adjusting for ILAR [7].

A range of therapies are now available to clinicians to treat JIA, including NSAIDs, steroids, intra-articular steroid injections, conventional synthetic DMARDs such as MTX, as well as biological DMARDs such as etanercept and adalimumab. There is evidence that early treatment within a so-called 'window of opportunity' may be associated with better outcomes [8]. A delay between symptom onset and treatment with MTX has been associated with reduced treatment response [9, 10] and the same has been observed with etanercept [11]. Studies have also shown a high response rate and higher rates of clinically inactive disease using early aggressive treatment including biologics [12, 13]. This is of particular importance as treatment with biologic therapies is often reserved for later in the disease course when patients have failed treatment with conventional DMARDs, suggesting that by this point the 'window of opportunity' may have passed.

The increasing array of treatment options alongside limited predictors of treatment response and poor outcomes makes the clinician's choice of therapy a difficult one. Clinicians must balance the need for appropriately aggressive therapies for some with the risk of overtreatment for others. The lack of clinical predictors of inflammatory outcome means that few prediction models exist and those that do generally perform poorly [7, 9, 14]. It is hoped that the addition of biological markers of

disease such as serum protein levels and genetic variants will improve the prediction of outcome. If we could predict which CYP will have poorer outcome they may be able to be fast tracked to a more aggressive treatment strategy, including earlier introduction of biologic therapy, allowing clinicians to make the most of the 'window of opportunity', improving overall outcomes, reducing long-term damage/disability and in turn the economic burden of disease [2, 15, 16].

There have been efforts to standardize criteria for the evaluation of patient outcome, with the validation of six core outcome variables (COVs) [17]: physicians global assessments (PGA) of overall disease activity; patient/parent assessment of overall well-being; number of joints with active arthritis; number of joints with limitation in motion; functional ability [e.g. validated translation of childhood HAQ (CHAQ)]; and an index of inflammation (either ESR or CRP). This led to the development of the Juvenile Arthritis Disease Activity Scores (JADAS), which incorporates four measures: PGA; parent/patient global assessment of well-being; a count of joints with active disease; and ESR [17, 18].

Efforts to identify genetic variants that predict disease outcome have been hampered by the lack of large datasets; therefore, few studies have been carried out. A study in 2003 looked at a cohort of 316 patients and found that persistent disease was predicted by the presence of *HLA-DRB1*08*; joint erosions were predicted by symmetric arthritis in addition to *HLA-DRB1*08* and *HLA-B27* in combination with *HLA-DRB*01* was a predictor of joint erosions in oligoarticular JIA [6]. A study of Portuguese JIA patients investigated single nucleotide polymorphisms (SNPs) associated with JIA susceptibility and genes with known function in the immune system [19]. A univariable analysis found significant associations between poor prognosis for allele A of rs6920220 (*TNFAIP3*), allele G of rs3761847 (*TRAF1/C5*) and allele G of rs7234029 (*PTPN2*), where poor prognosis was defined as CHAQ/HAQ >0.75 at the last visit and/or treatment with biological therapy. However, in multivariable analysis, none of the genetic associations withstood correction for multiple testing.

In contrast to the search for predictors of outcome, the search for JIA susceptibility variants has been extremely successful [20–22], identifying 24 SNPs associated with risk of disease at genome wide significance. However, many of the JIA susceptibility variants identified confer small effect sizes and therefore explain a small proportion of the heritability, as is the case in many complex phenotypes. One way to overcome the issue of power due to sample size limitations and small effect sizes is to use genetic risk scores (GRS), which combine the effects of multiple genetic variants into a single predictor. Combining risk alleles of selected SNPs into an aggregate GRS reduces the need to correct for multiple testing and allows a multigenic assessment of risk and can increase power to detect and overall effect [23–26]. Here for the first time we have used our existing knowledge of disease susceptibility to see if a GRS

composed of these variants can be used to predict disease outcome.

Patients and methods

Study population

This analysis includes CYP recruited to the Childhood Arthritis Prospective Study (CAPS), a prospective inception cohort recruiting from seven UK centres since 2001. Details of this cohort have been described previously [27]. CAPS was approved by the Northwest Multicentre Research Ethics Committee (NREC 02/8/104) and written informed consent from parents/guardians and where appropriate from participants was obtained.

In this analysis, CYP were included if they had a physician's diagnosis of JIA, categorised according to the ILAR classification, and were recruited to CAPS prior to 1 September 2017 (allowing at least 1 year follow-up), and had high-quality genotype data available. Patients with no ILAR category recorded were excluded. ILAR category was collected from the 1-year assessment to allow for categorization of persistent/extended oligoarthritis and for categories with extra-articular features (psoriatic JIA, enthesitis-related JIA) to become apparent. Non-European ancestry patients were also excluded.

SNP genotyping

Genotyping was carried out using the Illumina Infinium CoreExome and Infinium OmniExpress genotyping arrays as described in [22]. Briefly, sample level quality control was applied using the following exclusion criteria; call rate <0.98 and discrepancy between genetically inferred sex and database records. SNPs that were non-autosomal, had call rate <0.98 or minor allele frequency <0.01 were excluded. Imputation was performed in the Michigan Imputation server using SHAPEIT2 and Minimac3, and the Haplotype Reference Consortium reference panel. Following imputation SNPs were excluded based on minor allele frequency (MAF) <0.01 and imputation quality (r^2) <0.4. For more information, see López-Isac *et al.* [22].

Genetic risk score (GRS)

Twenty-four SNPs previously associated with JIA susceptibility at genome-wide significance level (P -value < 5×10^{-08}) were selected for inclusion in the GRS [20–22] (Supplementary Table S1, available at *Rheumatology* online); two HLA SNPs and 22 non-MHC risk SNPs. In STATA v14, data were coded by carriage of the JIA risk allele (0,1,2). Each SNP was then weighted by the beta coefficient (natural log-odds ratio) for susceptibility from the most recent genome-wide association study (GWAS) [22]. Risk alleles and beta coefficients used can be found in Supplementary Table S2, available at *Rheumatology* online. A GRS score was then generated by summing over the 24

SNPs. Using a weighted risk score is important as it takes into account regions that have a stronger predictive relationship with JIA (such as PTPN22) as compared with the more recently discovered SNPs.

Six SNPs out of the 24 were reported in both the ImmunoChip and GWAS studies (PTPN22, STAT4, ANKRD55, ATXN2, PTPN2 and TYK2). For PTPN22 and TYK2, the same SNP was reported in both studies. For the remaining four SNPs, different SNPs were reported. In these cases, we used the SNP reported in the latest GWAS as the population was more homogeneous (UK only vs US/UK/German) and were imputed to the latest reference panel. In-order to test for potential bias caused by a lack of independence between the discovery cohort (most recent GWAS in which the beta coefficients were generated [22]) and this test cohort, we removed overlapping samples from the discovery cohort and redefined the weights (beta coefficients). The beta coefficients from the discovery cohort were then compared with the newly defined beta coefficients using a scatterplot.

The GRS was then split into quintiles to identify high (quintile 5) and low (quintile 1) risk groups. This allowed analysis of the two extremes of the GRS as well as analysis of the continuous GRS score.

Outcome assessment

Our primary analyses considered change in the COVs (active and limited joint counts, physician's global assessment, parent global assessment, CHAQ and ESR from baseline to 1 year). As a secondary analyses, we also considered COVs at baseline.

The COVs were selected as they are routinely collected in clinic, and they make up the basis of the ACRpedi and the JADAS [18]. The individual components of these composite scores do not always correlate, therefore we have chosen to use the individual COVs to better reflect disease activity [2].

Data collection

Baseline data was collected at the point of first presentation to a paediatric or adolescent rheumatology clinic at one of seven centres across the UK and annually thereafter for 5 years. At each visit, patients (over age of 11 if they wish) or guardians were asked to complete a series of patient-reported outcome measures including the CHAQ. The CHAQ score totals 24 and is divided so that the final range is 0–3, with higher scores indicating poorer functional ability. Patients or guardians also complete a 100 mm pain visual analogue scale (VAS). Data from case notes also included ILAR category, the number of active and limited joints, the physician global assessment score and results of laboratory investigations including ESR (mm/h).

Statistical analysis

Missing outcome data (age at first presentation, age at onset, active joint count, limited joint count, physician

global assessment, parent global assessment, CHAQ, ESR and all change variables) were imputed over 20 imputations using multiple imputation by chained equations in STATA version 14.0 [28]; assuming data was missing at random.

Association of the GRS with change in COVs (or baseline COVs) was assessed via multivariable linear regression, through pooling models built over the imputed datasets using Rubins Rules [29]. All analyses were adjusted for ILAR category to determine the additional predictive power offered by the GRS. Analyses of change in COVs were adjusted for baseline values.

Results

Patient cohort


We considered 812 CYP with JIA with high-quality genotype data. Ninety-seven were excluded as they had non-European ancestry and two did not have a record of their ILAR category. This left 713 patients with genetic data and 1 year follow-up available (Table 1). Within the cohort, the median age of disease onset was 6.12 years and 65% were female. Oligoarticular JIA and RF negative polyarticular JIA were the most common JIA subtypes (Table 1).

Association of GRS with baseline measures

The GRS showed a normal distribution, with a mean score of 4.71 (s.d. 0.90) in our cohort (Fig. 1). Testing

the high- and low-risk groups (quintile 5 and 1 of GRS, respectively) for association with COVs showed that CYP in the high-risk group have a lower age at onset and age at presentation by ~2.5 years ($P \geq 0.001$) (median age at onset in low- and high-risk groups, respectively, 7.79 and 3.51) (median age at presentation in low- and high-risk groups, respectively, 9.06 and 4.05) (Table 2). The continuous GRS was associated with both age of onset and age at presentation

Fig. 1 Distribution of genetic risk score



The distribution of the GRS for 713 individuals included in the study. GRS: genetic risk score.

TABLE 1 Baseline characteristics

	Value = <i>n</i> (%) or median (IQR) at baseline	Patients with available data at baseline <i>n</i> (%)	Patients with available data at 1-year <i>n</i> (%)
Age at onset (years)	6.12 (2.65–10.36)	703 (98.60)	—
Age at first presentation (years)	6.89 (11.16–3.27)	708 (99.30)	—
Gender		713 (100)	—
Female	466 (65.36)	—	—
Active joint count	2 (1–6)	657 (92.15)	638 (89.48)
Limited joint count	1 (1–4)	657 (92.15)	638 (89.48)
Physician global assessment (10 cm VAS)	3.1 (1.80–5.40)	480 (67.32)	472 (66.20)
Patient/parent global assessment (10 cm VAS)	2.5 (0.60–5.10)	535 (75.04)	517 (72.51)
CHAQ (0–3)	0.75 (0.25–1.43)	543 (76.16)	509 (71.39)
ESR (mm/h)	21 (8–49)	513 (71.95)	299 (41.94)
ILAR		713 (100)	—
Systemic (%)	49 (6.87)	—	—
Persistent oligoarthritis (%)	305 (42.78)	—	—
Extended oligoarthritis (%)	43 (6.03)	—	—
RF negative polyarthritis (%)	171 (23.98)	—	—
RF positive polyarthritis (%)	23 (3.23)	—	—
ERA (%)	39 (5.45)	—	—
Psoriatic JIA (%)	54 (7.57)	—	—
Undifferentiated (%)	29 (4.07)	—	—

CHAQ: childhood assessment questionnaire; ERA: enthesitis-related arthritis; ILAR: International League of Associations for Rheumatology classification criteria; VAS: visual analogue scale.

TABLE 2 Association of high and low GRS groups with baseline measures

	Median (IQR) 1st quintile	Median (IQR) 5th quintile	coeff	95% CI	P-value	Coeff (adjusted for ILAR)	95% CI (adjusted for ILAR)	P-value (adjusted for ILAR)
Age at onset (years)	7.79 (3.26–11.49)	3.51 (1.83–7.57)	-2.55	-3.49, -1.60	<0.001	-2.41	-3.33, -1.48	<0.001
Age at first presentation (years)	9.06 (4.44–12.17)	4.05 (2.35–8.12)	-2.69	-3.67, -1.71	<0.001	-2.56	-3.50, -1.61	<0.001
Active joint count	2 (1–6)	2 (1–5.5)	-1.24	-2.96, 0.49	0.15	-1.00	-2.67, 0.66	0.23
Limited joint count	1 (0–4)	2 (1–4)	-0.09	-1.82, 1.63	0.91	0.10	-1.59, 1.79	0.91
Physicians global assessment (10 cm VAS)	3.5 (2–5.6)	3.6 (2.1–5.5)	0.19	-0.42, 0.79	0.54	0.22	-0.39, 0.83	0.47
Parents global assessment (10 cm VAS)	3.15 (0.65–5.15)	2.7 (0.8–5.2)	-0.06	-0.79, 0.66	0.86	-0.02	-0.75, 0.70	0.95
CHAQ	0.63 (0.25–1.38)	0.75 (0.13–1.36)	-0.05	-0.25, 0.15	0.64	-0.04	-0.25, 0.16	0.68
ESR (mm/h)	19.5 (7–51)	28 (11–56)	1.90	-5.90, 9.72	0.63	1.80	-6.02, 9.63	0.65

Association of high and low GRS groups with baseline measures. Median and IQRs are shown from the raw data prior to imputation. Regression modelling was carried out after imputation. The JIA GRS was split into quintiles: Q1 low risk, Q5 high risk. Association of the low and high risk groups was tested with each of the outcome measures, before and after adjusting for ILAR category. Bold *P*-values are significant. CHAQ: childhood HAQ; Coeff: β coefficient; IQR: interquartile range; VAS: visual analogue scale.

TABLE 3 Change core outcome variable from baseline to 1 year

	Median (IQR)	Patients with available data prior to imputation (%)
Change in active joint count	-1 (-5–0)	595 (83.45)
Change in limited joint count	-1 (-3–0)	595 (83.45)
Change in physician global assessment (0–10cm VAS)	-2.2 (-4.1–0.7)	357 (50.07)
Change in parent global assessment (0–10cm VAS)	-0.8 (-2.7–0)	403 (56.52)
Change CHAQ (0–3)	-0.125 (-0.75–0)	403 (56.52)
Change ESR (mm/h)	-15 (-46–0)	240 (33.66)

Median and interquartile range (IQR) for change variables prior to imputation. CHAQ: childhood HAQ; VAS: visual analogue scale.

(Supplementary Table S3, available at *Rheumatology* online).

Association of GRS with change in outcomes from baseline to 1 year

Table 3 shows the average change in each of the measured outcomes from baseline to 1 year. The median across all of the variables improved from baseline to 1 year follow-up. Prior to imputation there were high levels of missing data across all variables, with the highest for ESR as this is not routinely measured in UK paediatric rheumatology clinics unless a specific indication exists.

Multivariable linear regression showed that high or low GRS was not significantly associated with change in any of the outcome variables from BL to 1 year (Table 4).

Testing the continuous GRS for association with each outcome variable also showed no significant associations (Supplementary Table S4, available at *Rheumatology* online).

Discussion

Recent developments in treatments including the development of biologics, increased use of combination therapy and the move towards a treat-to-target strategy [30] have improved JIA outcomes generally, making remission an achievable target and have increased the expectations of clinicians, parents and patients. Prolonged synovial inflammation, if not properly treated, can lead to irreversible changes in the structure of the joint. Increasing our understanding of disease outcome

TABLE 4 Association of high and low GRS groups with change in outcome variable from baseline to 1 year

	Median (IQR) quintile 1	Median (IQR) quintile 5	Coeff (adjusted BL)	95% CI (adjusted BL)	P-value (adjusted BL)	Coeff (adjusted BL and ILAR)	95% CI (adjusted for BL and ILAR)	P-value (adjusted for BL and ILAR)
Change in active joint count	-1 (-4-0)	-1.5 (-4-0)	-0.39	-1.23, 0.45	0.35	-0.38	-1.22, 0.46	0.37
Change in limited joint count	-1 (-3-0)	-1 (-3-0)	-0.30	-1.09, 0.48	0.45	-0.27	-1.06, 0.52	0.50
Change in physician global assessment (10 cm VAS)	-2.35 (-4.35-0.55)	-2.75 (-4.4-0.9)	-0.42	-0.93, 0.09	0.11	-0.42	-0.94, 0.09	0.11
Change in parent global assessment (10 cm VAS)	-0.9 (-2.6-0.1)	-1 (-3-0)	-0.24	-0.87, 0.39	0.45	-0.24	-0.87, 0.38	0.44
Change in CHAQ	-0.25 (-0.63-0)	-0.13 (-0.63-0)	0.0005	-0.18, 0.18	0.99	0.0004	-0.18, 0.18	0.99
Change in ESR (mm/h)	-16 (-53-0.5)	-15 (-33-0)	3.98	-4.81, 12.77	0.36	3.74	-5.11, 12.60	0.40

Association of high and low GRS groups with change in outcome from baseline to 1 year. The JIA GRS was split into quintiles: Q1 low risk, Q5 high risk. Association of the low and high risk groups was tested with change in each of the outcome variables after adjusting for BL measures, before and after adjusting for ILAR category. BL: baseline; Coeff: β coefficient; IQR: interquartile range.

could allow us to identify patients who need more targeted therapy and therefore could be progressed to biologic or combination therapy more rapidly, reducing the likelihood of long-term damage. Indeed, studies have shown that early therapy results in better outcomes [11, 12, 31].

The ability to predict how a child's disease would progress would not only be of great value to clinicians, who want to personalise medicine to achieve the best outcomes, but also to families of JIA patients. Families can be desperate to understand how their child may be affected and what the future holds.

In order to identify genetic predictors of outcome in JIA, a genome-wide association study (GWAS) would be required. However, due to limited sample sizes of cohorts with both genetic and outcome data available, this would be underpowered.

In this study, we have used our existing knowledge of genetic variants associated with JIA susceptibility to investigate their utility as predictors of disease outcome. Due to the relatively small sample size for a genetics study (713 patients), we have used a GRS approach which, by combining risk alleles into an aggregate score, reduces the correction for multiple testing and also increases the power to detect an overall association [23–26].

We demonstrated that people with a higher GRS had a lower age of onset and age of presentation by at least 2.5 years on average; this may be due to the higher proportion of CYP with persistent oligoarticular JIA. This finding in part reinforces previous publications that have shown an association between age of onset in JIA and HLA alleles [32, 33]. No associations were observed between the GRS and change in any of the outcome measures from baseline to 1 year. This may be because we have focussed on susceptibility SNPs and that the SNPs driving susceptibility are independent to those driving disease progression and outcome, and themselves have no influence over the outcomes measured.

By splitting the cohort into high-risk and low-risk groups, and comparing the two extremes of the GRS, we hoped to enhance any associations. However, this did not benefit the analysis over and above using the continuous GRS, and resulted in even smaller sample sizes.

A limitation of our study is that we have not considered treatment in our analysis. This study focuses on genetic associations with the overall disease course of JIA as treated through standard practice across seven UK centres. It is less likely to be a confounder in our baseline analysis as the CYP were recruited prior to their first rheumatology visit and so it is unlikely they will have started any kind of DMARD or biologic at this point in time. We do not collect NSAID data prior to diagnosis. However, where we have MTX start dates (not available on all patients), we estimate around 20 cases in this analysis started a DMARD before their first paediatric rheumatology visit—likely as they were referred from adult rheumatology. We believe that this small number

will not significantly influence our results. If CYP were receiving treatment, it is unlikely that treatment would be directly associated with the GRS, as treatment does not differ due to genetics directly but by onset/severity, and therefore would not be a true confounder. The cohort represents a typical cohort of JIA patients treated according to current NHS guidelines in a rheumatology clinic; this means that any significant findings can be more easily applied to a real clinical setting.

The majority of genetic studies in JIA have been carried out in oligoarticular JIA and RF negative polyarticular JIA subtypes (referred to as polygos) as these are the most common categories of JIA and have been shown to be the most homogeneous in terms of genetics and clinical features. Conducting GWAS in other JIA subtypes has been more challenging due to the rarity of these categories. Here we have included all SNPs reaching genome-wide significance in the immunochip study that focussed on polygos [20], the most recent GWAS of JIA that included all subtypes [22] and a GWAS that identified SNPs associated with systemic JIA into our GRS [21]. Where the same genomic region was identified in multiple studies, but different lead (most strongly associated) SNPs were reported, we used the lead SNP from the most recent GWAS as this included all subtypes, was imputed to the most recent reference panel and included the most homogeneous population (European ancestry CYP from the UK only). All SNPs in the GRS were weighted by the beta coefficient (log-odds ratio) of the SNP from the published GWAS [22].

As some SNPs in our GRS were identified in polygo JIA, this may have missed SNPs associated with other JIA categories. We have attempted to control for this by adjusting for ILAR subtype. In addition, a proportion of the samples in our study will overlap with the Immunochip study and all of our samples will have been included in the GWAS, both studies identified the majority of the susceptibility SNPs included in our GRS; however, although this overlap is significant, if anything it should have biased the results to be more positive. Overlap in JIA cohorts is often avoidable due to the rarity of the disease and the lack of studies with comprehensive outcome data. In addition, we are testing the association of the GRS with different outcomes and therefore, as we are not trying to predict JIA, the independence of the samples is less important. To investigate this further, we created independence between the cohorts by re-running the susceptibility GWAS analysis excluding this test cohort to re-define the weights and showed this had no impact on the beta coefficients (Supplementary Fig. S1, available at *Rheumatology* online). Also of note, each locus is represented by a single index SNP and further independent effects would not be captured by the current GRS. This is perhaps a limitation of the current analyses and is something to consider for future exploration.

Another potential consideration is the role of index bias or Berkson's paradox [34], which occurs when

multiple risk factors for a condition are also risk factors for the disease itself. Researchers may commonly find that well-established risk factors do not associate with/have influence on disease risk. In such paradoxical cases, this is caused by limiting the patient cohort based on the disease itself and inducing correlation between the independent causes of disease. A popular example is known as the 'obesity paradox'. Obesity has been found to be a strong predictor of cardiovascular disease (CVD) in multiple studies, even in the absence of other risk factors [35]. However, it has also been observed that after the onset of CVD, those with a higher BMI tend to survive longer [36]. One explanation is that CVD patients with high BMI may have lower levels of other risk factors for CVD. If having lower levels of the other risk factors increases survival, then high BMI may also be associated with increased survival rates.

In this study, the SNPs in the GRS are risk factors for JIA, as are the outcome variables. By restricting the study population to JIA patients, this induces dependence between the previously independent risk factors, even when they would not be associated in the general population, creating a spurious association between the two risk factors. If possible, future studies should consider adjusting for environmental factors (e.g. prior infection, maternal smoking, etc.) that may increase susceptibility to JIA, to aid in understanding whether these susceptibility SNPs do have an independent association with outcome. It is important to be aware of this potential confounding factor; however, studies of outcome cannot be performed in the general population. The ideal scenario would be to conduct a large-scale GWAS of outcome in JIA. However, no GWAS of outcome has ever been carried out, due to the challenge of collecting adequate numbers of cases with detailed clinical outcome data as well as DNA.

In conclusion, we have shown that known genetic susceptibility variants are poor predictors of changes in JIA core outcomes over time and we do not support the use of GRS of JIA susceptibility for the prediction of these outcomes. A GWAS of outcome is now required to identify true genetic predictors. It is hoped that efforts to standardize data collection and collaboration between research groups will make this a possibility.

Acknowledgements

We thank all the children and young people and their families who have contributed to CAPS, as well as clinical staff and administrators. We thank Versus Arthritis for funding (UK grant number 20542). We also thank all principal investigators, clinical staff and research coordinators who have made this research possible, as well as members of the research team at the University of Manchester, UK. These include: G Cleary, E Baildam (Alder Hey Children's Hospital, UK), L Wedderburn (Great Ormond Street Hospital, UK), J Davidson (Royal Hospital for Sick Children, Edinburgh and Royal Hospital for Children, Glasgow, UK), A Chieng (Royal Manchester Children's Hospital, UK), F McErlane, H Foster (Royal

Victoria Infirmary, UK), C Ciurtin, Y Ioannou (University College London Hospital, UK) and W Thomson, K Hyrich (University of Manchester). The research team at the University of Manchester are additionally supported by the Centre for Epidemiology Versus Arthritis (UK grant number 21755) and the Centre for Genetics and Genomics Versus Arthritis (UK grant number 21754). This work is also supported by the NIHR Manchester Biomedical Research Centre and by the Manchester Academic Health Sciences Centre (MAHSC). The authors would also like to acknowledge the assistance given by IT Services and the use of the Computational Shared Facility at The University of Manchester.

We acknowledge support from the CLUSTER consortium. CLUSTER is supported by grants from the Medical Research Council (MRC) [MR/R013926/1] and Versus Arthritis [Grant: 22084], Great Ormond Street Hospital Children's Charity [VS0518] and Olivia's Vision. This work is supported by the NIHR GOSH BRC, the NIHR Manchester Biomedical Research Centre, the NIHR GOSH Biomedical Research Centre and the British Society for Rheumatology (BSR), and the 'UK's Experimental Arthritis Treatment Centre for Children, supported by Versus Arthritis (grant: 20621)'. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Members of the CLUSTER Consortium are as follows: Prof Lucy R. Wedderburn, Dr Melissa Kartawinata, Ms Zoe Wanstall, Ms Bethany R Jebson, Ms Alyssia McNeece, Ms Elizabeth Ralph, Mr Fatjon Dekaj, Ms Aline Kimonyo, Ms Fatema Merali, Ms Emma Sumner, Ms Emily Robinson (UCL GOS Institute of Child Health, London); Prof Andrew Dick, (UCL Institute of Ophthalmology, London); Prof Michael W. Beresford, Dr Emil Carlsson, Dr Joanna Fairlie, Dr Jenna F. Gritzfeld (University of Liverpool); Prof Athimalaipet Ramanan, Ms Teresa Duerr (University Hospitals Bristol); Prof Michael Barnes, Ms Sandra Ng, (Queen Mary University, London); Prof Kimme Hyrich, Prof Stephen Eyre, Dr Nophar Geifman, Prof Soumya Raychaudhuri, Prof Andrew Morris, Dr Annie Yarwood, Dr Samantha Smith, Dr Stevie Shoop-Worrall, Ms Saskia Lawson-Tovey, Dr John Bowes, Dr Paul Martin, Ms Melissa Tordoff, Mr Michael Stadler, Prof Wendy Thomson, Dr Damian Tarasek (University of Manchester); Dr Chris Wallace, Dr Wei-Yu Lin (University of Cambridge);

Dr Toby Kent, Dr Thierry Sornasse (AbbVie Inc.), Daniela Dastros-Pitei MD, PhD, Sumanta Mukherjee, PhD (GlaxoSmithKline Research and Development Limited.), Dr Jacqui Roberts (Pfizer Inc.), Dr Gil Reynolds Diogo [Swedish Orphan Biovitrum AB (publ) (Sobi)], Dr Helen Neale, Dr John Ioannou, Dr Hussein Al-Mossawi (UCB Biopharma SRL), The CLUSTER Champions.

Funding: A.Y. is funded by the NIHR Manchester Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the

NHS, the NIHR or the Department of Health. This work was also supported by the Centre for Epidemiology Versus Arthritis (UK grant number 21755) and the Centre for Genetics and Genomics Versus Arthritis (UK grant number 21754) at the University of Manchester, which are supported by the Manchester Academic Health Sciences Centre (MAHSC).

Disclosure statement: K.L.H. reports grants from BMS and Pfizer, and honoraria from AbbVie for speaking at an educational meeting, outside the submitted work. All other authors declare no other competing interests.

Data availability statement

Data available on request. The data underlying this article will be shared on reasonable request to the corresponding author.

Supplementary data

Supplementary data are available at *Rheumatology* online.

References

- 1 Petty RE, Southwood TR, Manners P *et al*. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. *J Rheumatol* 2004;31:390–2.
- 2 Shoop-Worrall SJW, Hyrich KL, Wedderburn LR *et al*. Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study. *Lancet Rheumatol* 2021;3:e111–21.
- 3 Van Dijkhuizen EHP, Wulffraat NM. Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review. *Ann Rheum Dis* 2015;74:1996–2005.
- 4 Glerup M, Herlin T, Twilt M. Clinical outcome and long-term remission in JIA. *Curr Rheumatol Rep* 2017;19:75.
- 5 Oliveira-Ramos F, Eusébio M, Martins FM *et al*. Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage. *RMD Open* 2016;2:e000304.
- 6 Flatø B, Lien G, Smerdel A *et al*. Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years. *J Rheumatol* 2003;30:386–93.
- 7 Shoop-Worrall SJW, Wu Q, Davies R, Hyrich KL, Wedderburn LR. Predicting disease outcomes in juvenile idiopathic arthritis: challenges, evidence, and new directions. *Lancet Child Adolesc Heal* 2019;3:725–33.
- 8 Minden K, Horneff G, Niewerth M *et al*. Time of disease-modifying antirheumatic drug start in juvenile idiopathic arthritis and the likelihood of a drug-free remission in young adulthood. *Arthritis Care Res* 2019;71:471–81.

- 9 Albarouni M, Becker I, Horneff G. Predictors of response to methotrexate in juvenile idiopathic arthritis. *Pediatr Rheumatol* 2014;12:35.
- 10 Albers HM, Wessels JAM, Van Der Straaten RJHM *et al.* Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis. *Arthritis Care Res* 2009;61:46–51.
- 11 Kearsley-Fleet L, Davies R, Lunt M, Southwood TR, Hyrich KL. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with juvenile idiopathic arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. *Rheumatology* 2016;55:840–7.
- 12 Tynjälä P, Vähäsalo P, Tarkiainen M *et al.* Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. *Ann Rheum Dis* 2011;70:1605–12.
- 13 Wallace CA, Giannini EH, Spalding SJ *et al.* Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. *J Rheumatol* 2014;41:1163–70.
- 14 Van Dijkhuizen EHP, Aidonopoulos O, Ter Haar NM *et al.* Prediction of inactive disease in juvenile idiopathic arthritis: a multicentre observational cohort study. *Rheumatology* 2018;57:1752–60.
- 15 Rypdal V, Arnstad ED, Aalto K *et al.* Predicting unfavorable long-term outcome in juvenile idiopathic arthritis: results from the Nordic cohort study. *Arthritis Res Ther* 2018;20:91.
- 16 Guzman J, Henrey A, Loughin T *et al.* Predicting which children with juvenile idiopathic arthritis will have a severe disease course: results from the ReACCh-Out cohort. *J Rheumatol* 2017;44:230–40.
- 17 Giancane G, Rosina S, Consolaro A, Ruperto N. Outcome scores in pediatric rheumatology. *Curr Rheumatol Rep* 2021;23:23.
- 18 Consolaro A, Ruperto N, Bazso A *et al.* Development and validation of a composite disease activity score for juvenile idiopathic arthritis. *Arthritis Care Res* 2009;61:658–66.
- 19 Mourão AF, Santos MJ, Mendonça S *et al.* Genetic predictors of poor prognosis in Portuguese patients with juvenile idiopathic arthritis: data from Reuma.pt. *J Immunol Res* 2015;2015:706515.
- 20 Hinks A, Cobb J, Marion MC *et al.* Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. *Nat Genet* 2013;45:664–9.
- 21 Ombrello MJ, Arthur VL, Remmers EF *et al.* Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. *Ann Rheum Dis* 2017;76:906–13.
- 22 López-Isac E, Smith SL, Marion MC *et al.* Combined genetic analysis of juvenile idiopathic arthritis clinical subtypes identifies novel risk loci, target genes and key regulatory mechanisms. *Ann Rheum Dis* 2021;80:321–8.
- 23 Chibnik LB, Keenan BT, Cui J *et al.* Genetic risk score predicting risk of rheumatoid arthritis phenotypes and age of symptom onset. *PLoS One* 2011;6:e24380.
- 24 Karlson EW, Chibnik LB, Kraft P *et al.* Cumulative association of 22 genetic variants with seropositive rheumatoid arthritis risk. *Ann Rheum Dis* 2010;69:1077–85.
- 25 Scott IC, Seegobin SD, Steer S *et al.* Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking. *PLoS Genet* 2013;9:e1003808.
- 26 Yarwood A, Han B, Raychaudhuri S *et al.* A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. *Ann Rheum Dis* 2015;74:170–6.
- 27 Adib N, Hyrich K, Thornton J *et al.* Association between duration of symptoms and severity of disease at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study. *Rheumatology* 2008;47:991–5.
- 28 StataCorp. Stata statistical software: release 14. College Station, TX: StataCorp LP, 2015.
- 29 Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley, 1987.
- 30 Schoemaker CG, Swart JF, Wulffraat NM. Treating juvenile idiopathic arthritis to target: what is the optimal target definition to reach all goals? *Pediatr Rheumatol* 2020;18:34.
- 31 Wallace CA, Giannini EH, Spalding SJ *et al.* Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. *Arthritis Rheum* 2012;64:2012–21.
- 32 Hollenbach JA, Thompson SD, Bugawan TL *et al.* Juvenile idiopathic arthritis and HLA class I and Class II interactions and age-at-onset effects. *Arthritis Rheum* 2010;62:1781–91.
- 33 Murray KJ, Moroldo MB, Donnelly P *et al.* Age-specific effects of juvenile rheumatoid arthritis-associated HLA alleles. *Arthritis Rheum* 1999;42:1843–53.
- 34 Choi HK, Nguyen US, Niu J, Danaei G, Zhang Y. Selection bias in rheumatic disease research. *Nat Rev Rheumatol* 2014;10:403–12.
- 35 Lavie CJ, Arena R, Alpert MA, Milani RV, Ventura HO. Management of cardiovascular diseases in patients with obesity. *Nat Rev Cardiol* 2018;15:45–56.
- 36 Elagizi A, Kachur S, Lavie CJ *et al.* An overview and update on obesity and the obesity paradox in cardiovascular diseases. *Prog Cardiovasc Dis* 2018;61:142–50.